Literature DB >> 1616884

Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T).

M Marugo1, D Bernasconi, L Miglietta, L Fazzuoli, F Ravera, S Cassulo, G Giordano.   

Abstract

The purpose of our study was to evaluate the effects of 5 alpha-dihydrotestosterone (DHT) and hydroxyflutamide (HF), alone or in combination, on androgen receptor (AR) dynamics and on cellular growth in cultured breast cancer cells (EVSA-T). The incubation of cells with DHT increased the concentration of nuclear AR after 24 and 48 h. HF was also able to promote the nuclear accumulation of AR after 24 and 48 h of treatment. When HF-treated cells are incubated with DHT, the nuclear AR concentration is lower than that found in cells treated with DHT alone. We conclude that HF acts by increasing nuclear accumulation of receptor-antiandrogen complexes. Moreover, DHT stimulates cell growth while HF has an inhibitory effect. Thymidine incorporation in cells also increased after DHT treatment and decreased after HF incubation. The HF-induced inhibition of cell growth persisted both after renewal of the medium and after the addition of DHT to cultures. It may be hypothesized that either DHT is converted to inactive metabolites or that HF exerts a persistent inhibitory effect. In the latter case, the antiandrogen action of HF could be exerted by retention of high levels of antiandrogen in cells or by such a depressed protein synthesis that the renewal of growth is slower than the 48 h period studied.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616884     DOI: 10.1016/0960-0760(92)90268-n

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  5 in total

1.  Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer.

Authors:  Andrei Anghel; Marius Raica; Catalin Marian; Sorin Ursoniu; Oana Mitrasca
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

2.  Growth inhibition of DMBA-induced rat mammary carcinomas by the antiandrogen flutamide.

Authors:  G Boccuzzi; E Tamagno; E Brignardello; M Di Monaco; M Aragno; O Danni
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).

Authors:  David G Cox; Hélène Blanché; Celeste L Pearce; Eugenia E Calle; Graham A Colditz; Malcolm C Pike; Demetrius Albanes; Naomi E Allen; Pilar Amiano; Goran Berglund; Heiner Boeing; Julie Buring; Noel Burtt; Federico Canzian; Stephen Chanock; Françoise Clavel-Chapelon; Heather Spencer Feigelson; Matthew Freedman; Christopher A Haiman; Susan E Hankinson; Brian E Henderson; Robert Hoover; David J Hunter; Rudolf Kaaks; Laurence Kolonel; Peter Kraft; Loic LeMarchand; Eiliv Lund; Domenico Palli; Petra H M Peeters; Elio Riboli; Daniel O Stram; Michael Thun; Anne Tjonneland; Dimitrios Trichopoulos; Meredith Yeager
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

4.  Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer.

Authors:  R E Hall; J O Aspinall; D J Horsfall; S N Birrell; J M Bentel; R L Sutherland; W D Tilley
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

Review 5.  The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.

Authors:  Elizabeth O Lillie; Leslie Bernstein; Giske Ursin
Journal:  Breast Cancer Res       Date:  2003-04-02       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.